ADAGENE INC
NASDAQ: ADAG (Adagene Inc.)
Last update: 8 hours ago2.85
-0.08 (-2.73%)
| Previous Close | 2.93 |
| Volume | 297,964 |
| Price / Sales | 16.50 |
| Price / Book | 2.21 |
| 52 Weeks Range |
| Operating Margin (TTM) | -17,082.39% |
| Diluted EPS (TTM) | -0.740 |
| Quarterly Revenue Growth (YOY) | -87.30% |
| Total Debt/Equity (MRQ) | 36.60% |
| Current Ratio (MRQ) | 2.30 |
| Operating Cash Flow (TTM) | -29.70 M |
| Levered Free Cash Flow (TTM) | -18.87 M |
| Return on Assets (TTM) | -21.92% |
| Return on Equity (TTM) | -55.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Adagene Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.70% |
| % Held by Institutions | 33.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Moneta Group Investment Advisors Llc | 30 Jun 2026 | 200,000 |
| Mill Creek Capital Advisors, Llc | 31 Mar 2026 | 199,610 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TAM MAN KIN | 2.97 | - | 2,000 | 5,940 |
| Aggregate Net Quantity | 2,000 | |||
| Aggregate Net Value ($) | 5,940 | |||
| Aggregate Avg. Buy ($) | 2.97 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TAM MAN KIN | Officer | 23 Sep 2026 | Buy (+) | 2,000 | 2.97 | 5,940 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |